Semarion raises £2.14 million GBP seed funding
Semarion’s cell assaying platform turns adherent cells into liquid reagents to enable novel drug screening methodologies
24-Feb-2022 -
Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, announced that it has closed a £2.14 million GBP seed funding round. The investment round was led by Parkwalk Advisors, ...
carrier material
cell assay
Cell screening systems
+6